I had previously mentioned that Antisense Therapeutics Limited (the creators of ATL1102) were seeking FDA guidance on the submission of ATL1102 for Phase II clinical trials. On October 24th 2014, in a press release,
Antisense Therapeutics announced that “the US Food and Drug Administration (FDA) has responded affirmatively to the Company’s plan to submit a U.S. Investigational New Drug (IND) application for initiation of longer term Phase IIb human trials of ATL1102 for the treatment of Multiple Sclerosis (MS)”.
Markie: Sorry. This should have been included in my post above Showing all 3 indications have had success in Phase 2—
- Forums
- ASX - By Stock
- PER
- Capricor Therapeutics
Capricor Therapeutics, page-50
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
8.1¢ | 8.1¢ | 8.0¢ | $20.93K | 260.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 91680 | 7.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.9¢ | 88379 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 91680 | 0.077 |
1 | 180000 | 0.076 |
4 | 186800 | 0.075 |
3 | 180866 | 0.074 |
1 | 53000 | 0.071 |
Price($) | Vol. | No. |
---|---|---|
0.079 | 88379 | 1 |
0.080 | 232232 | 1 |
0.081 | 12085 | 1 |
0.084 | 770250 | 3 |
0.085 | 412809 | 3 |
Last trade - 10.06am 20/08/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |